Arginine News and Research

RSS
Arginine is considered a semi-essential amino acid because even though the body normally makes enough of it, supplementation is sometimes needed. For example, people with protein malnutrition, excessive ammonia production, excessive lysine intake, burns, infections, peritoneal dialysis, rapid growth, urea synthesis disorders, or sepsis may not have enough arginine. Symptoms of arginine deficiency include poor wound healing, hair loss, skin rash, constipation, and fatty liver.

Arginine changes into nitric oxide, which causes blood vessel relaxation (vasodilation). Early evidence suggests that arginine may help treat medical conditions that improve with vasodilation, such as chest pain, clogged arteries (called atherosclerosis), coronary artery disease, erectile dysfunction, heart failure, intermittent claudication/peripheral vascular disease, and blood vessel swelling that causes headaches (vascular headaches). Arginine also triggers the body to make protein and has been studied for wound healing, bodybuilding, enhancement of sperm production (spermatogenesis), and prevention of wasting in people with critical illnesses.

Arginine hydrochloride has a high chloride content and has been used to treat metabolic alkalosis. This use should be under the supervision of a qualified healthcare professional.
Scientists establish link between autoimmune diseases and nanoparticles

Scientists establish link between autoimmune diseases and nanoparticles

Polymorphism ’protective in pneumococcal disease’

Polymorphism ’protective in pneumococcal disease’

Nouveau Life Pharmaceuticals launches new supplement for women with FSD

Nouveau Life Pharmaceuticals launches new supplement for women with FSD

Salt intake: why is it bad for you?

Salt intake: why is it bad for you?

Study describes new compounds that inhibit PRMT1 enzyme

Study describes new compounds that inhibit PRMT1 enzyme

Scientists discover new serine protease: NSP4

Scientists discover new serine protease: NSP4

FDA approves MedImmune's FluMist Quadrivalent vaccine

FDA approves MedImmune's FluMist Quadrivalent vaccine

ARCA biopharma receives method patent for treatment with bucindolol based on genetic targeting

ARCA biopharma receives method patent for treatment with bucindolol based on genetic targeting

KCC Director recognized for distinguished contributions to cancer care

KCC Director recognized for distinguished contributions to cancer care

Arginine may reactivate T-cells in patients with glioblastoma

Arginine may reactivate T-cells in patients with glioblastoma

Arginase-2 enzyme plays a major role in diabetic nephropathy

Arginase-2 enzyme plays a major role in diabetic nephropathy

Pivotal pediatric clinical study comparing Q/LAIV to FluMist meets primary endpoint

Pivotal pediatric clinical study comparing Q/LAIV to FluMist meets primary endpoint

Cyclic proteins transport drugs faster

Cyclic proteins transport drugs faster

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Study: AAKG supplementation has no significant impact on increased blood flow

Study: AAKG supplementation has no significant impact on increased blood flow

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

Natural recycling system, PPAR agonists can help protect children with heart defects

Natural recycling system, PPAR agonists can help protect children with heart defects

Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD

Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD

FDA files MedImmune's sBLA for quadrivalent intranasal nasal influenza vaccine, FluMist

FDA files MedImmune's sBLA for quadrivalent intranasal nasal influenza vaccine, FluMist

Female cancer survivors benefit from natural nutritional supplement

Female cancer survivors benefit from natural nutritional supplement